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Pirculating Endothelial Progenitor
ells Are Reduced in Peripheral Vascular
omplications of Type 2 Diabetes Mellitus
ian Paolo Fadini, MD,* Marta Miorin, BS,† Monica Facco, BS,† Sondra Bonamico,† Ilenia Baesso, BS,†
ranco Grego, MD,‡ Mirko Menegolo, MD,‡ Saula Vigili de Kreutzenberg, MD,* Antonio Tiengo, MD,*
arlo Agostini, MD,† Angelo Avogaro, MD, PHD*
adova, Italy
OBJECTIVES We sought to establish whether a reduction in endothelial progenitor cells (EPCs) has a
putative role in peripheral vascular disease (PVD) of type 2 diabetic patients.
BACKGROUND Peripheral vascular disease is a common and severe complication of diabetes mellitus.
Impaired collateralization of diabetic vasculopathy has been extensively shown, but causes
leading to its pathogenesis are not fully understood. Recently, EPCs have been found to
contribute to vascular repair and angiogenesis. Diabetes has been associated with low levels
of circulating EPCs, but no data are available in the literature on the relationship between
EPCs and PVD in diabetes.
METHODS Flow cytometric analysis was used to quantify circulating progenitor cells (CPCs, CD34)
and EPCs (CD34KDR) in 51 patients and 17 control subjects.
RESULTS The CPCs and EPCs from diabetic patients were reduced by 33% and 40%, respectively,
compared with healthy subjects (p  0.001). An inverse correlation was found between the
number of EPCs and the values of fasting glucose (r0.49, p 0.006). Peripheral vascular
disease was associated with a 47% reduction in EPCs (p  0.0001) and EPC levels directly
correlated with the ankle-brachial index (r  0.70, p  0.01). The subgroup of diabetic
patients with PVD also had reduced CPCs by 32% (p  0.037), whereas patients with
ischemic foot lesions had the lowest levels of both EPCs and CPCs (p  0.02).
CONCLUSIONS Our data demonstrate decreased EPC levels in diabetic patients and, for the first time, show
that PVD is associated with an extensively low number of EPCs. Depletion of circulating
EPCs in diabetic patients may be involved in the pathogenesis of peripheral vascular
complications. (J Am Coll Cardiol 2005;45:1449–57) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.067Cardiology Foundation
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aeripheral vascular disease (PVD) is a common and severe
omplication of diabetes mellitus (DM) and is characterized by
high prevalence, early development, and rapid progression. In
iabetes, there is also an impaired collateralization of vascular
schemic beds (1,2), but mechanisms that hinder ischemia-
nduced neovascularization in diabetes remain elusive (3).
See page 1458
Emerging evidence indicates that bone marrow-derived
ndothelial progenitor cells (EPCs) take part in postnatal
eovascularization (4). The EPCs co-express surface mark-
rs of both hematopoietic stem cells (CD34 and CD133)
nd endothelial cells (VEGF-R2, also known as KDR)
5,6). The EPCs express endothelial phenotype in culture,
romote in vivo re-endothelization (7), and are able to be
ncorporated into new vessels in animal models of hindlimb
schemia (8,9).
From the *Department of Clinical and Experimental Medicine, Division of
etabolic Diseases; †Department of Clinical and Experimental Medicine, Clinical
mmunology and Hematology; and ‡Department of Medical and Surgical Sciences,
ivision of Vascular Surgery, University of Padova, School of Medicine, Padova,
taly.w
Manuscript received August 20, 2004; revised manuscript received November 8,
004, accepted November 22, 2004.The EPCs are reduced in the presence of risk factors for
oronary artery disease (CAD), endothelial dysfunction,
ypercholesterolemia, smoking, and chronic renal failure
10–14). Lambiase et al. (15) have shown that poor coro-
ary collateral development is associated with reduced
umbers of circulating EPCs. Thus, depletion of circulating
PCs may contribute to both endothelial dysfunction, as an
arly event in the atherogenetic process, and poor collater-
lization, as a late event leading to clinical manifestations of
therosclerosis and cardiovascular disease progression.
Recently, circulating EPC reduction and dysfunction
ave been reported in both type 1 and type 2 diabetic
atients (16,17): these alterations are likely to be involved in
he pathogenesis of vascular complications of DM, but there
re no data on this topic currently available in the literature.
Therefore, the aim of this study was to evaluate circulat-
ng EPC numbers in type 2 diabetic patients with and
ithout PVD to establish whether an EPC reduction in
iabetic patients has a putative role in the pathogenesis of
eripheral vascular complications.
ETHODS
atients. Fifty-one patients were recruited for this study
nd classified into three groups: diabetics with (n  24) and
ithout (n  16) PVD and nondiabetics with PVD (n 
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EPC and Vascular Complications in Diabetes May 3, 2005:1449–571). Diabetic patients were selected from the Division of
etabolic Diseases, whereas nondiabetic patients were
elected from the Division of Vascular Surgery of the
niversity of Padova. Seventeen healthy control subjects
ere recruited from the local community. Ethics committee
pproval and written, informed consent from all subjects
ere obtained.
Lower extremity vascular disease was diagnosed by a
istory of claudication or rest pain, bilateral pulse examina-
ion (dorsal pedal, posterior tibial, popliteal, and femoral
rteries), ankle-brachial index (ABI), ultrasonography per-
ormed bilaterally at levels of femoral and popliteal arteries
n 25), and eventually angiography (n 7). The ABI was
able 1. Patient Characteristics
Characteristic
Diabetics With PVD
(n  24)
Diabetics Wit
(n  1
ge (yrs) 68.7 69.5
ender (% male) 70.1 56.2
MI (kg/m2) 27.5 29.3
aist (cm) 103.5 107.1
aboratory
Fasting glucose (mg/dl) 222.1 176.2
HbA1c (%) 8.9 10.9
Total cholesterol (mg/dl) 177.5 193.2
LDL cholesterol (mg/dl) 111.7 115.1
HDL cholesterol (mg/dl) 45.7 45.1
Triglycerides (mg/dl) 133.3 182.9
namnesis
Hypertension (%) 21 (88) 10 (63
CAD (%) 9 (37) —
PVD (%) 24 (100) —
Carotid (%) 15 (63) —
Lower extremity (%) 18 (75) —
Foot lesions (%) 8 (33) —
Retinopathy (%) 7 (29) 3 (19
Smoke (%) 3 (13) 3 (19
Familiarity (%) 9 (39) 4 (25
Metabolic syndrome (%) 12 (50) 5 (31
herapy
Insulin (%) 14 (58) 6 (38
Oral antidiabetics (%) 11 (46) 7 (44
Statin (%) 10 (42) 2 (13
Beta-blockers (%) 3 (13) 1 (6)
Calcium antagonists (%) 8 (33) 3 (19
ACE inhibitors (%) 18 (75) 13 (81
Diuretics (%) 16 (67) 4 (25
Antiaggregants (%) 15 (63) 6 (38
Anticoagulants (%) 2 (8) 1 (6)
p  0.05. Data are presented as the mean value or number (%) of subjects.
Abbreviations and Acronyms
ABI  ankle-brachial index
AER  albuminuria excretion rate
CAD coronary artery disease
CPC  circulating progenitor cell
DM  diabetes mellitus
EPC  endothelial progenitor cell
PVD  peripheral vascular diseaseACE  angiotensin-converting enzyme; BMI  body mass index; CAD  coronary
ow-density lipoprotein; PVD  peripheral vascular disease.easured as follows: patients were asked to rest supine for
0 min, then bilateral brachial and ankle (dorsalis pedis and
osterior tibial arteries) systolic blood pressures were mea-
ured through use of a hand-held 5-MHz Doppler scanning
robe. The ABI was calculated for each leg by dividing the
verage of the two ankle arterial pressures by the average of
he left and right brachial artery pressures. If brachial artery
ressures differed by 10 mm Hg, the highest brachial
rtery pressure was used. Patients with an ABI of 0.90
ere considered suggestive of PVD, whereas an ABI 1.40
as considered indicative of the presence of noncompress-
ble arteries.
Carotid atherosclerosis was assessed by bilateral carotid
rtery ultrasonography, and, when available, angiography (n 6).
Patients were considered to have CAD in the presence of
lectrocardiographic (ECG) findings unambiguously sug-
estive of a past myocardial infarction (n  3), a positive
CG at exercise test (n  2), an echocardiographic stress
est positive for inducible ischemia (n  3), or evidence of
ignificant coronary artery stenosis on a coronary angiogram
n  4).
In control subjects, the absence of type 2 DM and
PVD Controls With PVD
(n  11)
Controls Without PVD
(n  17)
p
Value
68.0 50.1* 0.001
90.9 41.2 0.04
26.6 26.6 NS
96.6* 93.6* 0.01
92.6* 93.7* 0.001
— — 0.03
196.0 166.5 NS
134.8 90.0 NS
52.0 55.0 NS
102.1 76.3 NS
7 (64) 6 (35)* 0.01
3 (27) — NS
11 (100) — NS
7 (63) — NS
6 (55) — NS
1 (10) — NS
— — NS
4 (36) 3 (18) NS
1 (9) 8 (47) NS
4 (36) 2 (12) NS
— — NS
— — NS
3 (27) 0* 0.006
1 (9) 0 NS
2 (18) 0 NS
4 (36)* 0* 0.001
3 (27)* 0* 0.001
3 (27)* 0* 0.001
0 0 NShout
6)
)
)
)
)
)
)
)
)*
)
)
)*
)artery disease; HbA1c  glycosylated hemoglobin; HDL and LDL  high- and
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May 3, 2005:1449–57 EPC and Vascular Complications in Diabetesmpaired glucose tolerance was documented by means of
asting glucose and 2-h glucose determination or oral
lucose tolerance test. The absence of cardiovascular dis-
ases was evaluated by a clinical history and examination,
arotid ultrasonography, and, when available, echocardiog-
aphy and coronary angiography.
In all patients body mass index, waist circumference, risk
actors for cardiovascular diseases, and pharmacologic his-
ory were assessed. Diabetic patients underwent a metabolic
valuation, including fasting glucose, immunoreactive insu-
in and C-peptide, glycated hemoglobin, and lipid profile.
enal function and albuminuria excretion rate (AER) were
lso evaluated. The presence of diabetic retinopathy was
ssessed by ophthalmologic examination. A diagnosis of the
etabolic syndrome was considered when patients met the
riteria of either the World Health Organization or the
dult Treatment Panel III from the National Cholesterol
ducation Program (18,19).
uantification of peripheral blood EPCs and CPCs by
ow cytometry. After an overnight fast, blood samples
ere obtained through a 20-gauge butterfly needle inserted
nto a forearm vein. All samples were processed after 1 to
igure 1. Circulating endothelial progenitor cells (EPCs) and circulating
rogenitor cells (CPCs) were identified by flow cytometry with low
ytoplasmic granularity and with the expression of cell surface antigens,
uch as CD34 and VEGF-R2 (KDR). (A) Representative flow cytometry
nalysis of a blood sample from a patient with high EPC count. (B) The
umber of EPCs from peripheral blood in the four groups of subjects.
ean values  SE. CTRL  control subjects; NS  not statistacally
ignificant. *p  0.05.h. Peripheral blood progenitor cells were analyzed for the Cxpression of cell-surface antigens with direct two-color
nalysis using fluorescein isothiocyanate (FITC)-conjugated
nd phycoerythrin (PE)-conjugated monoclonal antibodies
mAbs) by flow cytometric analysis (FACScan, Becton
ickinson, Sunnyvale, California), as previously reported
10,13,15). Briefly, 150 l of peripheral blood was incu-
ated with 10 l of FITC-conjugated anti-human CD34
Ab (Becton Dickinson) and 10 l of PE-conjugated
nti-human KDR mAb (R&D Systems Inc., Minneapolis,
innesota), followed by incubation at 4°C for 30 min.
ontrol isotype immunoglobulin (Ig)G1 and IgG2a anti-
ody were obtained from Becton Dickinson. The frequency
f peripheral blood cells positive for these reagents was
etermined by a two-dimensional side-scatter fluorescence
ot-plot analysis of the samples, after appropriate gating,
tained with the different reagents, as previously reported.
riefly, initially we gated CD34 peripheral blood cells and
hen examined the resulting population for dual expression
f KDR. Circulating progenitor cells (CPCs) were defined
s CD34 cells, whereas EPCs were defined as CD34
nd KDR cells. For FACS analysis, 5  105 cells were
cquired and scored using a FACScan analyzer (Becton
ickinson). Data were processed using the Macintosh
ELLQuest software program (Becton Dickinson). The
nstrument set-up was optimized daily by analyzing the
xpression of peripheral blood lymphocytes labeled with
nti-CD4 FITC/CD8 PE/CD3 PECy5/CD45 APC four-
olor combination.
tatistical analysis. Data are expressed as the mean value
SD, except as otherwise specified. Results from flow
ytometry are expressed as the number of cells per one
illion events. Comparisons between two or more groups
ere performed by the unpaired Student t test and analysis
f variance, respectively. The chi-square test was used for
ichotomous variables. Statistical associations between clin-
cal conditions or risk factors and cell counts were examined
y multivariate analysis using multiple linear regression.
orrelations of blood glucose and ABI with progenitor cells
ere assessed by Pearson’s coefficient (r), whereas the
orrelation between risk factors and progenitor cells was
ssessed by Spearman’s coefficient (rho).
Statistical significance was accepted if the null hypothesis
ould be rejected at p  0.05.
ESULTS
atient characteristics. Subject characteristics are pre-
ented in Table 1. The group of diabetic patients was
epresentative of a mixed type 2 diabetic population with
nd without macrovascular complications. Patients had a
ide range in their duration of diabetes (1 to 30 years).
wenty-two percent of patients (n  15) were receiving
tatin therapy for more than six months. Pathologic AER
30 mg per 24 h) was present in seven diabetic patients
ith PVD (29%) and four diabetics without PVD (25%).
hronic renal failure was present in one diabetic patient
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EPC and Vascular Complications in Diabetes May 3, 2005:1449–57ith PVD (1%) and in three diabetics without PVD
19%); none of these patients was on hemodialysis.
irculating EPCs and CPCs are reduced in type 2
iabetic patients. Flow cytometry was used to determine
he number of circulating peripheral blood CD34 cells
CPCs) and CD34KDR cells (EPCs). Because only
.02% to 0.07% of white blood cells where CD34, EPC
nd CPC counts were expressed for one million cytometric
vents. The EPC/CPC percent ratio was taken to represent
he extent of endothelial differentiation of generic circulat-
ng progenitors (Fig. 1A). Figure 1B illustrates EPC counts
n the four groups of subjects taken into consideration. The
nalysis of variance revealed a significant difference among
he groups (p 0.008). Differences were then analyzed with
he least significant difference post-hoc test.
Circulating EPC and CPC levels were significantly lower
n diabetic patients compared with healthy control subjects
42  21 vs. 71  38, p  0.001; and 247  95 vs. 370 
39, p  0.001, respectively) (Fig. 2A).
In diabetic patients, linear regression analysis revealed that
oth the number of EPCs and the EPC/CPC percent ratio
igure 2. (A) Diabetic patients have lower levels of circulating endothelial
CPCs) from diabetics display a similar reduction, indicating that the effe
irculating EPCs and EPC/CPC ratio were negatively correlated with b
ssociated with low absolute numbers of EPCs and low endothelial fract
iabetes mellitus.egatively correlated with the value of fasting glucose on day of Plood collection (r  0.49, p  0.006 and r  0.52, p 
.0007, respectively) (Fig. 2B). No significant correlations were
ound with glycated hemoglobin levels.
In the multivariate analyses, of all risk factors for athero-
clerotic disease, DM was the most significantly associated
ith a reduced EPC count (Table 2, Fig. 3A). In patients
ith a diagnosis of the metabolic syndrome, an EPC
eduction was even more evident (35  18 vs. 71  37,
 0.001) (Fig. 3B). Moreover, the number of risk
actors significantly correlated with both EPCs (rho 
0.48, p  0.003) and CPCs (rho  0.39, p  0.02)
Fig. 3C).
PCs and CPCs in patients with PVD. Of all clinical
onditions, PVD, but neither CAD nor microvascular
omplications (Table 2, Fig. 4), was associated with a strong
eduction in EPCs (37  22 vs. 70  37, p  0.0001) and
n the endothelial committed fraction of CPCs (14 9% vs.
3  13%, p  0.003), as compared with controls and all
on-PVD patients. On the contrary, the total number of
PCs did not statistically differ between vascular and
onvascular patients, but when considering all patients with
nitor cells (EPCs) when compared to controls. Circulating progenitor cells
diabetes per se is not specifically targeted to endothelial progenitors. (B)
glucose at time of blood collection. Higher glucose concentrations were
all progenitors. Mean values  SE. CTRL  control subjects; DM proge
ct of
loodVD, the subgroup of diabetics had significantly lower total
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May 3, 2005:1449–57 EPC and Vascular Complications in DiabetesPC counts (239  96 vs. 349  22, p  0.037) (Fig. 5A).
o differences in EPC and CPC levels were found between
arotid and lower extremity vascular disease (p  0.27). In
subgroup of 20 patients with PVD, both EPCs and CPCs
howed a direct and significant correlation with the values of
BI (Fig. 5B). Finally, diabetic patients with ischemic foot
esions due to end-stage PVD had even lower EPC and
PC numbers as compared with controls and diabetic
atients with PVD but without foot lesions (27  25 vs. 54
31, p  0.02 and 182  68 vs. 275  89, p  0.008,
espectively) (Fig. 5C).
The PVD patients on long-term statin therapy had
igher EPC levels (66  36 vs. 34  21, p  0.002) and
igher EPC/CPC percent ratios (26  11% vs. 12  7%, p
0.001) than did the patients with PVD who were not
reated with statins (Fig. 5D).
ISCUSSION
n this study, we show that: 1) type 2 diabetic patients have
40% mean reduction in peripheral blood EPC numbers; 2)
VD is characterized by very low EPC levels; and 3)
iabetic patients with peripheral vascular complications have
more profound reduction of all circulating progenitors.
The ability of organisms to spontaneously develop collat-
ral vessels represents an important response to vascular
cclusive diseases that partly determines the severity of
esidual tissue ischemia. Recent studies demonstrate that
ostnatal neovascularization does not rely exclusively on
prouting from existing vessels, but also involves a subset of
one marrow-derived progenitor cells (4). The mobilization
f EPCs from bone marrow to peripheral blood has been
Table 2. Multiple Linear Regression Analyses
and Risk Factors or Clinical Conditions (Indep
EPC Num
Beta Coefficient*
Risk factors (r2  0.27)
Smoke 0.233
Familiarity 0.084
Hypercholesterolemia 0.093
Gender (M) 0.188
Age 50 years 0.166
Diabetes 0.388
Obesity 0.111
Hypertension 0.142
ANOVA —
Clinical conditions (r2  0.17)
PVD 0.441
CAD 0.093
Retinopathy 0.022
AER 30 mg/24h 0.049
Chronic renal failure 0.090
ANOVA —
*Standardized regression coefficient. †One-sided p value.
AER  albuminuria excretion rate; ANOVA  analysis o
progenitor cell; M  male; other abbreviations as in Table 1eported in patients after acute myocardial infarction andcute coronary syndromes (20–22), but the literature lacks
ata on EPC variations in the presence of PVD.
Diabetes mellitus is characterized by endothelial dysfunc-
ion (23–25) and a three- to four-fold increase in cardio-
ascular risk, and diabetic vasculopathy is an important
ource of morbidity and mortality. Both type 1 and type 2
M have been associated with low levels and poor function
f circulating EPCs (16,17); however, no data are available
n the relationships between EPC pathophysiology and
ascular complications of DM.
In most published studies, circulating EPCs are deter-
ined by a culture method (10,11,14,16,17): EPCs are
efined as fibronectin-adherent peripheral blood-derived
ells uptaking acetylated low-density lipoprotein and bind-
ng Ulex-selectin in culture. However, these methods are
ime-dependent, and results vary largely on culture condi-
ions. In fact, endothelial cells cultured from peripheral
lood do not correspond to the actual population of circu-
ating EPCs but include mature circulating endothelial cells
nd monocyte/macrophage-derived cells assuming an endo-
helial phenotype in culture (26). Moreover, the amounts of
ultured EPCs do not provide information on the absolute
umber of circulating EPCs, because they depend not only
n the initial number of progenitors, but also on adhesion,
roliferation, and survival of plated EPCs, resulting from
omplex cellular interactions in the culture environment (27).
Recently, Peichev et al. (28) showed that CD34CD133
DR cells give rise to endothelial cells in vitro and that
hree-color fluorescence analysis of this cell subset may be
sed to identify and quantify circulating EPCs.
In this study, CD34 cells are defined as CPCs, whereas
D34KDR cells are defined as EPCs.
een Progenitor Cells (Dependent Variables)
nt Variables)
CPC Number
Value† Beta Coefficient* p Value†
(r2  0.25)
0.071 0.053 0.330
0.232 0.076 0.259
0.188 0.112 0.190
0.121 0.023 0.425
0.152 0.016 0.452
0.0007 0.543 0.0001
0.182 0.024 0.420
0.188 0.139 0.164
0.015 — 0.032
(r2  0.05)
0.0006 0.144 0.151
0.231 0.070 0.303
0.425 0.017 0.445
0.346 0.093 0.243
0.241 0.057 0.331
0.049 — 0.317
nce; CPC  circulating progenitor cell; EPC  endothelialBetw
ende
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pUsing a sensitive and specific technique, we found a
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EPC and Vascular Complications in Diabetes May 3, 2005:1449–57eduction in circulating EPCs in diabetic patients. We also
ound a significant correlation between plasma glucose at
he time of blood collection and absolute EPC numbers, as
ell as the EPC/CPC percent ratio (endothelial fraction of
ll CPCs). This finding indicates that the current rather
han the previous metabolic control could influence the
PC count and offers this possible explanation: a lower
igure 3. (A) Effect of individual risk factors on the numbers of endothelial
ulfilling diagnostic criteria for metabolic syndrome, EPC levels were even l
howed a significant negative correlation between the number of risk fac
orrelation with CPC counts was also present. Mean values  SE. IperC
ignificant.PC/CPC ratio may reflect a shortened peripheral survival pf EPCs rather than a weak bone marrow mobilization,
hich should also involve CPCs. According to this hypoth-
sis, preliminary data from our patients confirm that rapid
etabolic recompensation is followed by an increase in the
PC number and EPC/CPC ratio (data not shown). It has
een reported that high glucose is able to induce apoptosis
f cultured endothelial cells (29). Given their endothelial
enitor cells (EPCs) and circulating progenitor cells (CPCs). (B) In patients
while CPCs were reduced to a lesser extent. (C) Linear regression analysis
in diabetic patients and their circulating EPC levels. A milder negative
hypercholesterolemia; MS  metabolic syndrome; NS  not statisticallyprog
ower,
tors
h henotype, EPCs exposed to high glucose may undergo
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May 3, 2005:1449–57 EPC and Vascular Complications in Diabetespoptosis. Future studies are needed to determine the
echanisms involved in EPC reduction in DM, and we are
urrently trying to establish the effects of acute hyperglyce-
ia on circulating EPCs in vivo.
Our data also suggest that DM is the most relevant risk
actor associated with EPC reduction: low circulating EPCs
ould account for both endothelial dysfunction and poor
ollateralization typical of diabetics, although we did not
erform functional vascular studies on our patients. How-
ver, the finding of a lower EPC count in patients with the
etabolic syndrome as compared with those without, to-
ether with the negative correlation between the number of
isk factors and progenitor cell counts (Fig. 3), underscores
he importance of risk factor clustering in determining the
educed EPC blood content.
Circulating EPC and CPC reduction has been demon-
trated in several clinical conditions characterized by high
ardiovascular risk (11–14), although data on stable athero-
clerotic disease are few and ambiguous.
In this study, we report for the first time, a profound
eduction in circulating EPCs in patients with PVD. In our
atients, CAD was characterized by a mild and nonsignif-
cant reduction in EPC levels. This finding apparently
ontradicts other data in the literature, but it should be
oted that Vasa et al. (10) reported a 40% reduction of
PCs in a cohort of patients with CAD, compared with
ge-matched healthy volunteers; however, their CAD group
ncluded not only patients with stable disease, but also
atients with acute coronary syndromes or myocardial in-
arction—clinical events known to be followed by EPC
ncreases (20,21). Heeschen et al. (30) found no differences
n CD34CD133 cells between patients with chronic
yocardial ischemia and healthy controls, but reported
oorer angiogenic properties of progenitor cells from pa-
ients than from controls. Thus, it appears that the literature
rovides no definite data on EPC reduction in stable CAD.
The ABI is considered the most objective diagnostic test
or lower extremity vascular disease and is also a reliable
igure 4. Association between any individual clinical condition present in
irculating progenitor cell (CPC) levels. Only PVD was associated with
omplications had no effect on levels of EPCs and CPCs. Mean values  S
ailure; NS  not statistically significant.arker of cardiovascular risk (31): the strong correlation Eetween progenitor cell levels and the ABI suggests that the
eduction in vascular progenitor cells is related to the
everity of PVD, as well as to global cardiovascular risk in
oth diabetic and nondiabetic patients with PVD (Fig. 5B).
Among all patients selected for the presence of PVD,
hose with diabetes had a lower number of EPCs, and those
ith foot lesions complicating end-stage obstructive vascu-
ar disease had the lowest values of both CPCs and EPCs
Fig. 5). Although our study was cross-sectional and does
ot establish cause-effect relationships, these data suggest
hat an EPC reduction may have a role in the pathogenesis
f PVD. Thus, we would like to propose a possible
athophysiologic model. Diabetes mellitus and clustered
isk factors reduce circulating EPC levels: an EPC decrease
ontributes to endothelial dysfunction, accelerates athero-
enetic processes, and leads to vascular diseases. Further-
ore, EPC depletion impairs collateralization and favors
omplications, such as foot lesions. Our observations also
ffer a possible explanation for the unsatisfactory outcome of
atients with critical lower extremity ischemia who have
een enrolled in clinical trials of angiogenic therapy with
ytokines (32–34). Delivering cytokines (the software) is not
ufficient in the absence of the cells primarily involved in
ew vessel generation (the hardware) (35).
Statin therapy has been associated with an EPC increase.
t the time of the study, 42% of diabetic patients with PVD
ere taking statins: the actual severity of EPC reduction in
VD is unmasked when only patients not treated with
tatins are considered (Fig. 5D).
Recently, interest in the possible use of EPCs for cellular
herapy of critical ischemia syndromes has increased (9,36–
8). Nonetheless, it should be noted that EPC dysfunction
ight limit the use of autologous peripheral blood- or bone
arrow-derived progenitors for angiogenic therapy
3,9,17). However, in vitro demonstration of EPC dysfunc-
ion is highly unspecific due to the presence of alterations in
he whole pool of peripheral blood mononuclear cells (3),
nd because it does not provide reliable information on
study population and variations in endothelial progenitor cell (EPC) and
cantly reduced EPC numbers, while pathologic AER and microvascular
ER  albuminuria excretion rate 30 mg per 24 h; CRF  chronic renalthe
signifi
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VD patients, rather than in vitro functional impairment of
heir EPCs.
onclusions. This study reports a reduction in circulating
PCs in type 2 DM and a further, progressive EPC and
PC decrease in diabetic patients with PVD and distal
esions, in relation to ABI values. These data may offer a
ew pathophysiologic hypothesis for the high incidence of
igure 5. (A) Patients with peripheral vascular disease (PVD) had lower l
on-vascular subjects. In all PVD patients circulating progenitor cells (CPC
n diabetic patients with PVD were CPC counts significantly reduced. (B)
he ankle brachial index (ABI) in patients with lower extremity vascular d
f non-compressible arteries due to calcific sclerosis. (C) Patients with foot
PC and CPC levels than PVD patients without foot lesions. (D) Circulat
herapy than in nontreated patients. Mean values  SE. DM-PVD  diabascular damage in patients with type 2 DM.eprint requests and correspondence: Dr. Gian Paolo Fadini,
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